<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032025000400361</article-id>
<article-id pub-id-type="doi">10.35366/120522</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome metabólico cardiorrenal: mecanismos patogénicos]]></article-title>
<article-title xml:lang="en"><![CDATA[Cardio-renal metabolic syndrome: pathogenic mechanisms]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Arreguín]]></surname>
<given-names><![CDATA[Roxana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santibañez Silva]]></surname>
<given-names><![CDATA[Violeta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Regules Silva]]></surname>
<given-names><![CDATA[Sonia de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Angeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>23</volume>
<numero>4</numero>
<fpage>361</fpage>
<lpage>366</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032025000400361&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032025000400361&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032025000400361&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El síndrome cardiorrenal (SCR) es una enfermedad multiorgánica que incluye enfermedades que resultan en un aumento del volumen circulante por una interacción en la disfunción entre corazón, riñón y el síndrome metabólico (SM). El síndrome metabólico cardiorrenal se define como un grupo de trastornos que incluye la presencia de diabetes tipo 2, enfermedad renal crónica e insuficiencia cardiaca que se asocia a morbilidad y mortalidad relevantes, ya que los pacientes con insuficiencia cardiaca tienen una prevalencia cuatro veces mayor de diabetes tipo 2 (20%) y ésta a su vez duplica el riesgo de enfermedad cardiovascular (ECV). De igual forma, la prevalencia de enfermedad renal crónica aumenta al 40% en personas con diabetes tipo 2 y al 50% en pacientes con insuficiencia cardiaca. Dentro de su fisiopatología coexisten varios desórdenes hemodinámicos (cambios en las resistencias vasculares sistémicas y pulmonares, aumento de la presión venosa central, deterioro del gasto cardiaco y sobrecarga de fluidos) con desórdenes metabólicos, neurohormonales e inflamatorios (degeneración aterosclerótica, especies reactivas de oxígeno [ERO], producción de óxido nítrico, disfunción endotelial y fibrosis de tejido) que llevan a un deterioro de la perfusión sistémica y aumento de riesgo cardiovascular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Cardiorenal syndrome (CRS) is a multi-organ disease that includes conditions resulting in increased circulating volume due to the interaction between dysfunctions of the heart, kidneys, and metabolic syndrome (MS). Cardiorenal metabolic syndrome is defined as a group of disorders that includes the presence of type 2 diabetes, chronic kidney disease, and heart failure, which are associated with significant morbidity and mortality since patients with heart failure have a four-fold higher prevalence of type 2 diabetes (20%), which in turn doubles the risk of cardiovascular disease (CVD). Similarly, the prevalence of chronic kidney disease increases to 40% in people with type 2 diabetes and 50% in patients with heart failure. Its pathophysiology involves various hemodynamic disorders (changes in systemic and pulmonary vascular resistances, increased central venous pressure, impaired cardiac output, and fluid overload) along with metabolic, neurohormonal, and inflammatory disorders (atherosclerotic degeneration, reactive oxygen species [ROS], nitric oxide production, endothelial dysfunction, and tissue fibrosis) that lead to impaired systemic perfusion and increased cardiovascular risk.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diabetes]]></kwd>
<kwd lng="es"><![CDATA[enfermedad renal crónica]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[síndrome cardiorrenal]]></kwd>
<kwd lng="en"><![CDATA[diabetes]]></kwd>
<kwd lng="en"><![CDATA[chronic kidney disease]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[cardiorenal syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marassi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fadini]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cardio-renal-metabolic connection: a review of the evidence]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2023</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>195</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gembillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Visconti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Giusti]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Siligato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiorenal syndrome: new pathways and novel biomarkers]]></article-title>
<source><![CDATA[Biomolecules]]></source>
<year>2021</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1581</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chakraborty]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nemer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dasgupta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varian]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on the pathophysiology and treatment of cardiorenal syndrome]]></article-title>
<source><![CDATA[Cardiol Res]]></source>
<year>2020</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-88</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mattina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Argano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brunori]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lupo]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Raspanti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Monaco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical complexity and diabetes: a multidimensional approach for the management of cardiorenal metabolic syndrome]]></article-title>
<source><![CDATA[Nutr Metab Cardiovasc Dis]]></source>
<year>2022</year>
<volume>32</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2730-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Méndez Fernández]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Vergara Arana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olivella San Emeterio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Azancot Rivero]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano Colome]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Soler Romeo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiorenal syndrome and diabetes: an evil pairing]]></article-title>
<source><![CDATA[Front Cardiovasc Med]]></source>
<year>2023</year>
<volume>10</volume>
<page-range>1185707</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poplawski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Radmilovic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montina]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Metz]]></surname>
<given-names><![CDATA[GAS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiorenal metabolic biomarkers link early life stress to risk of non-communicable diseases and adverse mental health outcomes]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2020</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13295</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akiyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yajima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2023</year>
<volume>14</volume>
<page-range>1111984</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricciardi]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Gnudi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular growth factors as potential new treatment in cardiorenal syndrome in diabetes]]></article-title>
<source><![CDATA[Eur J Clin Invest]]></source>
<year>2021</year>
<volume>51</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoveling]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Liefbroer]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Bültmann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Smidt]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding socioeconomic differences in metabolic syndrome remission among adults: what is the mediating role of health behaviors?]]></article-title>
<source><![CDATA[Int J Behav Nutr Phys Act]]></source>
<year>2021</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>147</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosiorek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Biegus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rozentryt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hurkacz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zymli&#324;ski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiorenal syndrome: Decongestion in heart failure across wide spectrum of kidney pathophysiology]]></article-title>
<source><![CDATA[Adv Clin Exp Med]]></source>
<year>2022</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>445-55</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales Villegas]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<source><![CDATA[El síndrome metabólico cardiovascular renal: una reconstrucción del concepto de síndrome metabólico impulsada por la evidencia terapéutica 2013-2023 [Internet]]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Aguascalientes ]]></publisher-loc>
<publisher-name><![CDATA[Centro de Investigación Cardiometabólica de Aguascalientes]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hinds]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Stec]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bilirubin safeguards cardiorenal and metabolic diseases: a protective role in health]]></article-title>
<source><![CDATA[Curr Hypertens Rep]]></source>
<year>2019</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>87</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Yen]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>7833</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uric acid and the cardio-renal effects of SGLT2 inhibitors]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2019</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1291-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&#8217;Elia]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bayliss]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Weinrauch]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diabetic cardiorenal nexus]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2022</year>
<volume>23</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>7351</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scappaticcio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maiorino]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Bellastella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2021</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>189</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Che]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2023</year>
<volume>14</volume>
<page-range>1125693</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ndumele]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Rangaswami]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Neeland]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salud cardiovascular, renal y metabólica: un consejo presidencial de la Asociación Americana del Corazón]]></article-title>
<source><![CDATA[Circulación]]></source>
<year>2023</year>
<volume>148</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1606-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
